title: Modulation by the noble gas argon of the catalytic and thrombolytic efficiency of tissue plasminogen activator.
abstract: Argon has been shown to provide cortical as well as, under certain conditions, subcortical neuroprotection in all models so far (middle cerebral artery occlusion, trauma, neonatal asphyxia, etc.). This has led to the suggestion that argon could be a cost-efficient alternative to xenon, a metabolically inert gas thought to be gold standard in gas pharmacology but whose clinical development suffers its little availability and excessive cost of production. However, whether argon interacts with the thrombolytic agent tissue plasminogen activator, which is the only approved therapy of acute ischemic stroke to date, still remains unknown. This latter point is not trivial since previous data have clearly demonstrated the inhibiting effect of xenon on tPA enzymatic and thrombolytic efficiency and the critical importance of the time at which xenon is administered, during or after ischemia, in order not to block thrombolysis and to obtain neuroprotection. Here, we investigated the effect of argon on tPA enzymatic and thrombolytic efficiency using in vitro methods shown to provide reliable prediction of the in vivo effects of both oxygen and the noble inert gases on tPA-induced thrombolysis. We found that argon has a concentration-dependent dual effect on tPA enzymatic and thrombolytic efficiency. Low and high concentrations of argon of 25 and 75 vol% respectively block and increase tPA enzymatic and thrombolytic efficiency. The possible use of argon at low and high concentrations in the treatment of acute ischemic stroke if given during ischemia or after tPA-induced reperfusion is discussed as regards to its neuroprotectant action and its inhibiting and facilitating effects on tPA-induced thrombolysis. The mechanisms of argon-tPA interactions are also discussed.
authors.affiliation: CSSS Alphonse-Desjardins, Centre Hospitalier Affilié Universitaire Hôtel-Dieu de Lévis, Université Laval, Lévis, QC, Canada. helene_david@ssss.gouv.qc.ca
authors.forename: Hélène N
authors.initials: HN
authors.lastname: David
authors.forename: Benoît
authors.initials: B
authors.lastname: Haelewyn
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Risso
authors.forename: Jacques H
authors.initials: JH
authors.lastname: Abraini
mesh_terms: D000818:Animals; D001128:Argon / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D008297:Male; D010100:Oxygen / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
chemical_list: D005343:Fibrinolytic Agents; D001128:Argon; D010959:Tissue Plasminogen Activator; D010100:Oxygen